Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 5:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 18,635 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Adult Clear all
Terminated No phase listed Observational

Dopamine and Motor Learning in Cerebral Palsy

NCT02839733
View directory record Official record
Conditions
Cerebral Palsy
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
5 Years to 25 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Oct 23, 2026, 5:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability of SC Formulation and Japanese Ethnobridging Study for PRA023

NCT05354349
View directory record Official record
Conditions
Healthy
Interventions
PRA023 IV Low Dose, PRA023 SC, Placebo IV, Placebo SC, PRA023 IV High Dose
Drug
Lead sponsor
Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 55 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jan 16, 2024 · Synced Oct 23, 2026, 5:36 PM EDT
Completed Phase 3 Interventional Results available

Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine

NCT03211858
View directory record Official record
Conditions
Type 1 Diabetes Mellitus-Type 2 Diabetes Mellitus
Interventions
Insulin aspart, NovoLog/NovoRapid, Insulin glargine (HOE901)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
597 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
42
States / cities
Little Rock, Arkansas • Concord, California • Escondido, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Oct 23, 2026, 5:36 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Phase 1/2, Randomized, Placebo-controlled, Observer-blinded Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Multivalent Group B Streptococcus Vaccine In Healthy Adults 18 To 49 Years Of Age

NCT03170609
View directory record Official record
Conditions
Group B Streptococcal Infections
Interventions
Multivalent group B streptococcus vaccine, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 49 Years
Enrollment
365 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
4
States / cities
Stockbridge, Georgia • Bardstown, Kentucky • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 2, 2019 · Synced Oct 23, 2026, 5:36 PM EDT
Not listed Not applicable Interventional

Chronic Care Management for Adults at FQHCs

NCT02136732
View directory record Official record
Conditions
Any Condition in N73.0 Specified as Chronic
Interventions
Active self-management intervention, Attention control phone calls
Other
Lead sponsor
Washington State University
Other
Eligibility
45 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated May 18, 2017 · Synced Oct 23, 2026, 5:36 PM EDT
Completed No phase listed Observational Results available

Comparing State Payer Strategies to Prevent Unsafe Opioid Prescribing

NCT03932799
View directory record Official record
Conditions
Opioid Use, Opioid-Related Disorders
Interventions
Prospective prior authorization (PA) with hard stops in Washington, Retrospective review (RR) with prescriber notification in Ohio
Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
5,411 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Columbus, Ohio • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 23, 2026, 5:36 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer

NCT04077099
View directory record Official record
Conditions
NSCLC
Interventions
REGN5093
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
8
States / cities
Orange, California • Washington D.C., District of Columbia • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 23, 2026, 5:36 PM EDT
Terminated Phase 3 Interventional Results available

Adjunctive SPD489 to Antipsychotic Medication in Clinically Stable Adults With Persistent Predominant Negative Symptoms of Schizophrenia

NCT01738698
View directory record Official record
Conditions
Schizophrenia
Interventions
SPD489 40mg, SPD489 100mg, SPD489 160mg, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Irving, Texas
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Oct 23, 2026, 5:36 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer

NCT03816163
View directory record Official record
Conditions
Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
Interventions
zolbetuximab, nab-paclitaxel, gemcitabine
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
393 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
25
States / cities
Fullerton, California • Whittier, California • Meriden, Connecticut + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 23, 2026, 5:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Plant-Derived Pfs25 VLP-FhCMB Malaria Transmission Blocking Vaccine in Healthy Adults

NCT02013687
View directory record Official record
Conditions
Malaria
Interventions
Pfs25 VLP- FhCMB
Biological
Lead sponsor
Fraunhofer, Center for Molecular Biotechnology
Industry
Eligibility
18 Years to 50 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Oct 23, 2026, 5:36 PM EDT
Completed Phase 2 Interventional

Campath-1H + FK506 and Methylprednisolone for GVHD

NCT00109993
View directory record Official record
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions
alemtuzumab, methylprednisolone, tacrolimus
Biological · Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
6
States / cities
New York, New York • Cleveland, Ohio • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2010 · Synced Oct 23, 2026, 5:36 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma

NCT02348216
View directory record Official record
Conditions
Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma (TFL), Primary Mediastinal B-cell Lymphoma (PMBCL), High Grade B-cell Lymphoma (HGBCL)
Interventions
Axicabtagene Ciloleucel, Fludarabine, Cyclophosphamide, Levetiracetam, Tocilizumab, Dexamethasone, High-dose methylprednisolone, Bendamustine, Rituximab, Doxorubicin, Prednisone, Vincristine, Ifosfamide, Carboplatin, Etoposide, Gemcitabine, Oxaliplatin, Cisplatin, Methylprednisolone
Biological · Drug
Lead sponsor
Kite, A Gilead Company
Industry
Eligibility
18 Years and older
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
23
States / cities
Gilbert, Arizona • Duarte, California • La Jolla, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Oct 23, 2026, 5:36 PM EDT
Not yet recruiting Phase 3 Interventional Accepts healthy volunteers

iCanQuit Smoking Cessation Among Hispanic Adults

NCT06811038
View directory record Official record
Conditions
Cigarette Smoking-Related Carcinoma
Interventions
iCanQuit Smartphone App Smoking Cessation Program, Nicotine Gum, Nicotine Patch, Nicotine Lozenge, Survey Administration, Interview
Device · Drug · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
854 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 23, 2026, 5:36 PM EDT
Completed No phase listed Observational

Removing Fluid Above Breathing Tubes in the Operating Room

NCT01110109
View directory record Official record
Conditions
Pneumonia, Ventilator-Associated
Interventions
Not listed
Lead sponsor
Medtronic - MITG
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Oct 26, 2010 · Synced Oct 23, 2026, 5:36 PM EDT
Suspended Not applicable Interventional Accepts healthy volunteers

The Effects of a High Protein Breakfast on Appetite and Sleep in Young Adults

NCT03031132
View directory record Official record
Conditions
Appetite and General Nutritional Disorders
Interventions
HP-Beverage Breakfast, HP-Solid Breakfast, Breakfast Skipping
Behavioral
Lead sponsor
Purdue University
Other
Eligibility
20 Years to 32 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated May 19, 2017 · Synced Oct 23, 2026, 5:36 PM EDT
Terminated No phase listed Observational

Percutaneous Interventions in Adults With CHD

NCT00266916
View directory record Official record
Conditions
Congenital Disorders
Interventions
Not listed
Lead sponsor
Children's Healthcare of Atlanta
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2006
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 23, 2007 · Synced Oct 23, 2026, 5:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Clinical Trial of MK-4646 With Bictegravir/Emtricitabine/Tenofovir Alafenamide and Dolutegravir in Healthy Adult Participants (MK-4646)

NCT07532304
View directory record Official record
Conditions
Healthy
Interventions
Bictegravir/emtricitabine/tenofovir alafenamide, Dolutegravir, MK4646
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Anniston, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 23, 2026, 5:36 PM EDT
Completed Phase 2 Interventional Results available

Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT01707004
View directory record Official record
Conditions
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), de Novo Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
Interventions
decitabine, fludarabine phosphate, busulfan, cyclophosphamide, tacrolimus, mycophenolate mofetil, filgrastim, total-body irradiation, allogeneic bone marrow transplantation, laboratory biomarker analysis
Drug · Biological · Radiation + 2 more
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Oct 23, 2026, 5:36 PM EDT
Completed Phase 1 Interventional

Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit

NCT01527838
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease, Chronic Lymphocytic Leukemia (CLL), Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL)
Interventions
Single FT1050 treated UCB unit
Biological
Lead sponsor
Fate Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Boston, Massachusetts • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 12, 2016 · Synced Oct 23, 2026, 5:36 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry Disease

NCT03737214
View directory record Official record
Conditions
Fabry Disease
Interventions
Lucerastat
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
14
States / cities
Birmingham, Alabama • Irvine, California • Oakland, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 23, 2026, 5:36 PM EDT
Completed No phase listed Observational Results available

Effect of Multi-Media Tool on Enrollment in Oncology Clinical Trials

NCT02020252
View directory record Official record
Conditions
Lung Cancer, Gastric Cancer, Pancreatic Cancer
Interventions
Testing an interactive technology in a diverse health literary population
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 10, 2021 · Synced Oct 23, 2026, 5:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity Study of Ad26-ENVA and Ad35-ENV HIV Vaccines in Healthy HIV-uninfected Adults

NCT01215149
View directory record Official record
Conditions
HIV Infections
Interventions
Ad35-ENV vaccine, Ad26.ENVA.01 vaccine, Placebo Control
Biological
Lead sponsor
International AIDS Vaccine Initiative
Network
Eligibility
18 Years to 50 Years
Enrollment
218 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 17, 2012 · Synced Oct 23, 2026, 5:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

MEDI-557 Adult Dosing

NCT01562938
View directory record Official record
Conditions
Respiratory Syncytial Virus
Interventions
Placebo, MEDI-557
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 45 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 7, 2013 · Synced Oct 23, 2026, 5:36 PM EDT
Completed Phase 2 Interventional Results available

Bevacizumab in Treating Patients With Unresectable Nonmetastatic Liver Cancer

NCT00055692
View directory record Official record
Conditions
Adult Primary Hepatocellular Carcinoma, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
Interventions
bevacizumab
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 29, 2016 · Synced Oct 23, 2026, 5:36 PM EDT